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Summary
 
Cyclophilins have been suggested to act as leukocyte chemotactic factors produced in the
course of inflammation. Therefore we looked for the presence of cyclophilins in the synovial
fluids (SF) from patients with rheumatoid arthritis (RA). Peptidyl prolyl 
 
cis
 
–
 
trans
 
 isomerase ac-
tivity (PPIase) was measured in SF from knee punctures of 26 patients with RA and five
patients with knee osteoarthritis (OA). PPIase was detected in SF from RA patients, but not in
samples from OA patients. Enzyme activity was sensitive to inhibition by cyclosporin A (IC
 
50
 
 
 
5
 
28–50 nM). Estimated concentrations of the SF-derived cyclophilin based on the enzyme
activity were in the range of 11 to 705 nM. The presence of cyclophilin in the SF showed
disease correlation; its concentration correlated with the number of cells in the SF (
 
r
 
 
 
5
 
 0.91,
 
P
 
 
 
,
 
0.0001) and with the percentage of neutrophils in the cellular infiltrate and was higher in
more acute cases of joint swelling. In immunoblots of partially purified preparations of SF from
RA patients, an 
 
z
 
18-kD protein band reacted with polyclonal antibodies that recognize cyclo-
philin A and B, but not with antibodies specific for cyclophilin B. Sequencing of this protein
revealed identity of the NH
 
2
 
-terminal amino acids with those of human cyclophilin A. The
finding is unexpected since cyclophilin B rather than A is generally regarded as the secreted iso-
form, the presence of cyclophilin A being confined to the cytoplasm. Our data support the hy-
pothesis that cyclophilins may contribute to the pathogenesis of inflammatory diseases, possibly
by acting as cytokines. This may offer a possible explanation of the effectiveness of cyclosporin
A in RA, in addition to the known immunosuppressive effects of the drug.
 
I
 
nflammation is accompanied by a characteristic accumu-
lation of polymorphonuclear leukocytes (PMN) in the
tissue, which is observed in a variety of pathological condi-
tions. In the case of rheumatoid arthritis (RA), the synovial
fluid in affected joints of patients contains large numbers of
different exudate cells; as the disease progresses, the PMNs
become the predominant cell type. These cells may con-
tribute to the eventual tissue destruction observed in RA
and other arthritic conditions, since they are a major source
of enzymes including those which degrade cartilage. There-
fore, identification of factors responsible for the recruitment
of PMNs is crucial for the understanding of the pathogene-
sis of synovial inflammation.
We have demonstrated that the chemokine IL-8 (also
designated human neutrophil activating peptide, NAP-1) is
present in synovial fluids (SF) in a high proportion of RA
cases (1). The major activities of this peptide include neu-
trophil activation and induction of neutrophil and lympho-
cyte chemotaxis (2, 3). The observed correlation between
concentration of IL-8 in SF and cellular influx into the
joint was strongly suggestive of a pathogenic role for IL-8
in RA. 
During our search for additional factors that are responsi-
ble for the attraction of PMNs, we asked whether cyclo-
philin(s) might be involved in synovial inflammation. Cy-
clophilins are a family of proteins characterized by their
prolyl 
 
cis
 
-
 
trans
 
 isomerase activity and the ability to bind cy-
closporin A (4, 5). More recently, secreted cyclophilins
have been described (6–9), and human, rodent and bovine
cyclophilins have been shown to be chemotactic to poly-
morphonuclear leukocytes and monocytes (9, 10). In this
paper, we demonstrate the presence of cyclophilin A in
synovial fluids of patients with RA.
 
Materials and Methods
 
Patients and Synovial Fluids.
 
Knee punctures were taken from
26 RA patients and five osteoarthritis (OA) patients. RA patients
(6 male, 20 female) had a mean age of 52 yr (range 36–66); their
mean disease duration was 6 yr (0.5–16). OA patients (1 male, 2
female) had a mean age of 68 (62–78); mean disease duration was
8 yr (6–12). Knee punctures were performed under sterile condi-
tions. The volume of synovial fluid (SF) removed was between 4
and 30 ml; SF was collected in sterile EDTA tubes. The SF was
centrifuged immediately at 1,000 
 
g
 
 for 15 min; the cell-free su-
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pernatant was transferred into plastic tubes and stored at 4
 
8
 
C until
analysis. Cell number and differential cell counts were determined
in a Coulter counter. Synovial cells were analyzed for morpho-
logical criteria and cell lysis in a FACS
 
Ò
 
. Synovial IgM rheuma-
toid factor (IgMRF) determination was done by a standard
nephelometric method (11). All RA patients were treated with
different disease modifying antirheumatic drugs, e.g., antimalari-
als, methotrexate, azathioprine, or oral gold derivatives; 12 of the
patients were additionally treated with oral steroids. All OA pa-
tients were treated with non-steroidal antirheumatic drugs.
 
Proteins and Antibodies.
 
Recombinant human cyclophilins A and
B were provided by M. Zurini and Sandoz Basle; the cyclophilin
B corresponds to the mature form of the protein lacking the
NH
 
2
 
-terminal leader sequence (6). Polyclonal antibodies against
purified recombinant human cyclophilin A were raised in rabbits
and purified via DEAE Sephadex and protein A–Sepharose (Phar-
macia, Uppsala, Sweden) chromatography; these antibodies show
strong cross-reaction with cyclophilin B. Polyclonal antibodies
against recombinant cyclophilin B or against the COOH-termi-
nal peptide of cyclophilin B (12), both raised in rabbits, were
kindly provided by Prof. G. Spik (University of Lille, France);
these antibodies do not react with cyclophilin A in Western blots.
Recombinant human NAP-1/IL-8 was produced and purified as
previously described (2). Goat polyclonal antibodies and mouse
monoclonal antibodies against IL-8 have been described before (13).
 
Enzyme Assay.
 
Peptidyl prolyl 
 
cis
 
-
 
trans
 
 isomerase activity in
the cell-free supernatants of synovial fluids was measured using the
assay essentially as described by Kofron et al. (14). In brief, sam-
ples (50 
 
m
 
l) or purified cyclophilin B as control were diluted with
50 mM Hepes, 100 mM NaCl, pH 8.0 (875 
 
m
 
l), in a photometer
cuvette and cooled to 10
 
8
 
C. Then, 50 
 
m
 
l of 
 
a
 
-chymotrypsin
(Serva, Heidelberg, Germany) (10 mg/ml in 1 mM HCl) were
added, and the reaction was started by addition of 25 
 
m
 
l 4 mM
 
N
 
-succinyl-Ala-Ala-Pro-Phe
 
 p
 
-nitroanilide (Bachem, Bubendorf,
Switzerland) in trifluoroethanol/470 mM lithium chloride. The
increase in absorbance at 390 nm was recorded with a Cary 1E
spectrophotometer. Data points were obtained every 0.5 s and fit-
ted to a first-order rate law to obtain the reaction rate in units of
absorbance (ABS) per min. In the case of inhibition experiments
compounds were added from stock solutions in ethanol before
addition of the chymotrypsin; solvent concentration did not ex-
ceed 2%. Isomerization rates observed in presence of different
concentrations of inhibitor were used to calculate IC
 
50 
 
values.
 
Protein Purification and Identification.
 
For partial purification of
the cyclophilin, samples of cell-free supernatants of synovial fluids
were subjected to fractionated ammonium sulfate precipitation (30–
60% wt/vol). The precipitate was redissolved in against 10 mM
Hepes, pH 8.0, 1 mM DTE, 0.1 mM EDTA and dialyzed against
the same buffer. This solution was then passed through a Super-
ose 12 column (2.6
 
 3 
 
60 cm; Pharmacia) at flow of 2 ml/min of
the same buffer; 4-ml fractions were collected. Protein was de-
tected by measuring absorbance at 280 nm, and enzyme activity
by the isomerase assay as above.
SDS–polyacrylamide gel electrophoresis was performed on gels
containing 20% acrylamide using the Pharmacia PhastSystem de-
vice. Gels were either stained with Coomassie Brillant Blue or
blotted to nitrocellulose membranes. For Immunodetection, blots
were incubated with primary antibodies, and reactive bands were
visualized with biotinylated second antibody followed by the
ECL detection system (Amersham, Braunschweig, Germany) and
exposure to x-ray film.
Automated sequence analysis of protein samples electroblotted to
Glassybond (Biometra, Göttingen, Germany) (15) was performed
on a model 470A amino acid sequencer coupled to an on-line
PTH-amino acid analyzer, model 120A (Applied Biosystems,
Foster City, CA) with reverse-phase PTH C-18 micro-bore col-
umn (2.1 
 
3 
 
220 mm) using a standard gradient system (16).
 
Results
 
To investigate the presence of cyclophilins in synovial
fluids, we chose to measure the peptidyl prolyl 
 
cis
 
–
 
trans
 
 iso-
merase activity associated with the proteins in a spectro-
photometric assay using a synthetic peptide substrate (14).
SF from knee punctures of patients with RA or OA were
tested. Isomerase activity was detected in 26 out of 27 sam-
ples from RA patients. The only RA synovial fluid that did
not show activity was derived from a patient (PF) that had
been treated with a human IL-1 receptor antagonist, a
treatment that reduces monocytotrophic synovial activity
(17). In the five samples of OA patients no enzyme activity
was present.
Since cyclophilins but also FK 506 binding proteins
(FKBP) are able to isomerize the substrate used here, we
performed experiments with specific inhibitors of the en-
zymes. The isomerase activity in the synovial fluids of the
RA patients could be inhibited with cyclosporin A, an in-
hibitor of cyclophilins, but not with the macrophilin FK
506 (Fig. 1). This indicates that isomerization activity is due
to a cyclophilin rather than to a FKBP. In five different SF,
50% inhibition of the activity was observed with cyclo-
sporin A at concentrations of 28 to 50 nM.
To quantify the cyclophilin-like activity in the synovial
fluids, a calibration curve (concentration versus reaction rate)
Figure 1. Time course of the peptidyl prolyl cis-trans isomerase activity.
(Triangles) Cyclophilin B added (25 nM final concentration); (filled circles)
50 ml synovial fluid from a patient with RA (patient WA, left knee); (open
squares) same as filled circles, but 20 mM FK 506 included; (open circles)
Same as filled circles, but 20 mM cyclosporin A included; (filled squares) 50 ml
synovial from a patient with OA (patient HU) added; (+) no synovial
fluid added, i.e., substrate cleavage proceeding in the absence of isomerase
(control). Note that the last three curves coincide. 
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with purified recombinant cyclophilin A was prepared, which
was linear in the range of 2 to 30 nM (regression curve:
 
m
 
M cyclophilin A 
 
5
 
 5.07 
 
3
 
 rate [ABS/min] 
 
1
 
 0.927, 
 
r
 
 
 
5
 
0.997, 
 
n
 
 
 
5
 
 13). Using this calibration and assuming that the
isomerase activity in the SF is due to an enzyme with spe-
cific activity similar to cyclophilin A, an estimate of the cy-
clophilin concentration was obtained (Table 1). Cyclophi-
lin concentrations in the range of 11 to 705 nM were
found.
One may ask whether the cyclophilin activity in the flu-
ids arises by active secretion of protein from synovial cells
or merely as a consequence of cellular destruction. We,
therefore, analyzed the synovial cells by FACS
 
Ò
 
 for mor-
phological criteria in a forward side scatter mode; there was
 
Table 1.
 
Concentration of Cyclophilin-like Activity in Synovial Fluids (Knee Punctures) and Disease Parameters
 
Disease
Patient
initials
Cyclophilin
concentration
 
*
 
Synovial fluid
cell count Neutrophils IgMRF
Duration of
joint swelling
 
nM cc 10
 
3
 
/ml % wk
 
RA BE 159 22,700 92
 
1,
 
1
RA PF
 
‡
 
,
 
2 1,200 68
 
1
 
4
RA HS 100 25,600 94
 
2,
 
1
RA MK 87 20,500 89
 
1,
 
1
RA MA 237 32,400 96
 
2,
 
1
RA FB 48 16,300 85
 
1
 
2
RA GL 242 53,500 96
 
2,
 
1
RA BR 11 10,600 80
 
1
 
4
RA HR 33 14,800 84
 
1
 
3
RA SD 89 22,600 90
 
1
 
1
RA PA 24 13,000 79
 
1
 
3
RA WA, left
 
§
 
117 31,700 96
 
1,
 
1
RA WA, right
 
§
 
49 24,600 88
 
1,
 
1
RA HG 13 9,700 78
 
1.
 
4
RA FH 30 13,200 82
 
2
 
4
RA LR 70 20,200 87
 
1
 
2
RA KM 89 23,400 90
 
2
 
1
RA HN 29 16,400 83
 
1
 
4
RA LA 28 15,100 80
 
2.
 
4
RA HH 24 11,600 78
 
2.
 
4
RA KK 92 23,400 90
 
1,
 
1
RA KL 573 68,200 92
 
1,
 
1
RA NN 105 27,300 90
 
1,
 
1
RA KP 17 11,000 88
 
1
 
2
RA PM 147 32,600 94
 
1,
 
1
RA AA 705 82,900 96
 
2,
 
1
RA EM 110 30,800 91
 
1,
 
1
OA HU
 
,
 
2
 
,
 
100 NA
 
i
 
2.
 
4
OA SN
 
,
 
2
 
,
 
100 NA
 
2.
 
4
OA SL
 
,
 
2 120 NA
 
2.
 
4
OA PE ,2 ,100 NA 2 4
OA KR ,2 ,100 NA 2. 4
* Concentrations were obtained from a calibration curve with cyclophilin B (see text), and are thus based on the assumption that the PPlase activity
is due to an enzyme with specific activity similar to cyclophilin B.
‡Treatment with recombinant human IL1 receptor antagonist.
§SF from patient WA was first taken from the left knee and subsequently intraarticular cortisone instillation was given into that knee. 24 h later, SF
from the right knee was taken.
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no evidence of significant cell lysis (less than 1% in samples
of all patients).
We also determined the cell counts in the synovial fluids;
a linear correlation was observed between the cell count
and the cyclophilin concentration (Fig. 2 A; correlation co-
efficient  r  5 0.91, P ,0.0001). Furthermore, SF with
higher enzyme concentration contained the higher per-
centage of neutrophils in the cellular infiltrate (Fig. 2 B). In
addition, we noted that the highest cyclophilin concentra-
tions were all observed in patients with a short anamnestic
duration of joint swelling (<1 wk) (Table 1). No correla-
tion was seen between the titer of synovial IgM RF and
cyclophilin concentration (Table 1).
To identify the protein responsible for the cyclophilin-
like activity, we performed a fractionation of synovial fluids.
Two separate experiments were performed with SF pools
of patients KK, NN, and PH and patients KL and AA.
First, fractionated ammonium sulfate precipitation was per-
formed; the enzymatic activity precipitated between 20 and
60% saturation. This was followed by gel filtration chroma-
tography on Superose 12; this step separated the bulk of
protein contained in the SF from the enzymatic activity.
In the pooled fractions containing the isomerase activity,
SDS gel electrophoresis followed by Coomassie staining re-
vealed the presence of a protein band that comigrates with
cyclophilin A besides some other contaminating bands (Fig.
3 A). Using a polyclonal antiserum raised against cyclophi-
lin A which cross-reacts with cyclophilin B, an immunore-
active band migrating to the same position as cyclophilin A
was detected (Fig. 3 B). This protein did not react with an-
tibodies specifically recognizing cyclophilin B (not shown).
To further substantiate the assumption that the SF contain
cyclophilin A, we performed NH2-terminal sequencing of
the 18-kD protein partially purified from pooled SF of
patients KL and AA after blotting from SDS gels. The se-
quence of the first 20 NH2-terminal amino acids was deter-
mined to Val-Asn-Pro-Thr-Val-Phe-Phe-Asp-Ile-Ala-Val-
Asp-Gly-Glu-Pro-Leu-Gly-Arg-Val-Ser. This is identical
to the known sequence of human cyclophilin A (18).
It has been reported that recombinant cyclophilin A is
recognized on Western blots by antibodies directed against
IL-8 (19). Using a polyclonal antiserum as well as a mono-
clonal antibody against IL-8 (13) we observed cross-reac-
tion with the authentic cyclophilin from synovial fluids,
too (immunoblot not shown).
Discussion
Cyclophilins are a family of highly conserved and ubiq-
uitous proteins that possess peptidyl cis-trans isomerase ac-
tivity (4, 5). This activity is thought to be important for
protein folding in vivo (20). The most abundant isoform,
cyclophilin A, has been described as a cytosolic protein
while the more recently discovered cyclophilin B is located
in the endoplasmatic reticulum (21, 22). Cyclophilin B is
known to be retained in reticulum vesicles by its COOH-
terminal extension (23), but its appearance in human milk
(6) and in the extracellular compartment of embryonic
chick tissues (7) indicated that it is also a secreted protein.
Furthermore, it has recently been shown that cyclophilin B
is released by human leukocytes into the blood (12). Be-
sides their enzymatic activity, a possible function of cyclo-
philins as cytokines has been suggested; a secreted cyclo-
philin was identified as a proinflammatory product of
lipopolysaccharide-activated murine macrophages (9), bo-
vine and human cyclophilin A were shown to be chemo-
tactic for eosinophils and neutrophils (10), and embryonic
chick cyclophilin B was found to possess growth factor ac-
tivity (7). Moreover, cyclophilin B binds specifically to the
surface of T cells (24, 25).
Here we demonstrated that cyclophilin A is present in the
synovial fluids of patients with RA, as evidenced by (a) its
enzymatic activity and (b) the occurrence of an immunore-
active protein of the same molecular weight and with the
same NH2-terminal sequence known for this protein. The
Figure 2. Correlation of cyclophilin-like protein concentration with
total cell counts in synovial fluids of RA patients (filled circles) and with
percentage of neutrophils (open triangles).
Figure 3. SDS–polyacrylamide gel electrophoresis of partially purified
cyclophilin A from synovial fluids of patients (KL and AA) with RA. Lane
1, recombinant cyclophilin B; lane 2, recombinant cyclophilin A; lane 3,
pooled fractions of gel filtration chromatography containing the synovial
cyclophilin activity. A Gel (20%) stained with Coomassie brillant blue.
(B) Immunoblot developed with antibodies which recognize cyclophilins
A and B. Positions of marker proteins (M) are indicated.979 Billich et al. Brief Definitive Report
natural human protein shows similar sensitivity to inhibi-
tion of its PPIase activity by cyclosporin A (IC50 between
28 and 50 nM) as recombinant cyclophilin A (IC50 5 27
nM under similar conditions).
So far only human cyclophilin B has been regarded to be
a secreted isoform, while the presence of cyclophilin A was
thought to be confined to the cytoplasm (26). To our
knowledge, this is the first time that cyclophilin A has been
detected in an extracellular fluid or inflammatory exudate
in man. However, a proinflammatory cyclophilin secreted
by lipopolysaccharide-activated murine macrophages has
been shown by partial sequencing to be identical to the in-
tracellular murine cyclophilin A (9). It appears that the cy-
clophilin in the synovial fluids is secreted by the cells at the
site, rather than being released as a consequence of cell de-
struction. Whereas we cannot completely exclude that cy-
toplasmic cyclophilin A and the protein contained in the
SF have minor variations of sequence or posttranslational
modifications, their immune reactivity and enzymatic prop-
erties do not suggest major differences.
The appearance of the cyclophilin A in SF shows corre-
lation with disease parameters; its concentration correlates
with the amount of cells in the fluid, with the percentage
of neutrophils in the cellular infiltrate and is higher in more
acute cases of joint swelling. Further studies will have to
clarify whether the cyclophilin A purified from SF has
chemotactic activity, as has been reported for the recombi-
nant protein (10). If in fact cyclophilin A from the natural
source can be shown to be chemotactic, it will be interest-
ing to study to which extent it may contribute to the neu-
trophil activating activity in synovial fluids of RA patients,
in view of the presence of IL-8 and other cytokines in the
exudate. Seitz et al. (27) reported that 90% of the neutro-
phil-activating activity of synovial fluids from RA patients
could be neutralized by a polyclonal anti–IL-8 antiserum;
as a caveat, the cross-reactivity of antibodies against IL-8
and cyclophilin (see our findings and the results of Bang
et al. [19]) may have led to an overestimation of the role of
IL-8. In fact, more recently Strieter et al. (28) reported an
only 27 to 57% reduction in neutrophil chemotactic activ-
ity with their IL-8 neutralizing antibodies, which indicates
a substantial role for other chemotactic proteins.
Cyclosporin A is an immunosuppressive drug used for
prevention of organ rejection, but is also useful in inflam-
matory diseases like psoriasis. It is also effective in RA (for
review see reference 29). The mode of action of the immu-
nosuppressive activity of cyclosporin A is understood in
considerable detail (20): the compound does not exert its
effect by inhibiting the isomerase activity of cyclophilin,
but its binding enables cyclophilin to form a tertiary com-
plex with the protein phosphatase calcineurin; this interac-
tion leads to modulation of the response of T cells to im-
mune stimuli on the transcriptional level. However, based
on the chemotactic properties of cyclophilins it has been
proposed that a second, complementary mechanism of ac-
tion may exist (9, 24, 30), namely direct interaction of the
drug with secreted cyclophilin isoforms. In view of this
still open debate, our finding that cyclophilin A in fact is
present in biological fluids of patients with an inflammatory
disease that is responsive to therapy with cyclosporin A
should stimulate further investigation of the role of cy-
closporin A as an antiinflammatory compound and of the
cytokine-like effects of cyclophilins.
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